Ferro Desideri, Lorenzo; Artemiev, Dmitri; Bernardi, Enrico; Paschon, Karin; Zandi, Souska; Zinkernagel, Martin; Anguita, Rodrigo (2023). Investigational drugs inhibiting complement for the treatment of geographic atrophy. Expert opinion on investigational drugs, 32(11), pp. 1009-1016. Taylor & Francis 10.1080/13543784.2023.2276759
Full text not available from this repository.INTRODUCTION
Geographic atrophy (GA) is a progressive form of age-related macular degeneration (AMD) that leads to severe visual impairment and central vision loss. Traditional treatment options for GA are limited, highlighting the need for new therapeutic approaches. In recent years, targeting the complement system has emerged as a promising strategy for the treatment of GA.
AREAS COVERED
This expert opinion article reviews the investigational drugs inhibiting the complement cascade for the treatment of GA. Specifically, it focuses on the recent FDA approved pegcetacoplan, a C3 complement inhibitor, and avacincaptad pegol, a C5 complement inhibitor, highlighting their potential efficacy and safety profiles based on clinical trial data.
EXPERT OPINION
FDA approval of intravitreal pegcetacoplan and avacincaptad pegol marks significant progress in the landscape of GA treatment. However, variable results from trials underscore the complex nature of GA and the importance of patient selection. Complement inhibition holds promise, but ongoing research is vital to refine treatment strategies and offer improved outcomes for GA patients.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology |
UniBE Contributor: |
Ferro Desideri, Lorenzo, Artemiev, Dmitri, Bernardi, Enrico, Paschon, Karin, Zandi, Souska Sophie, Zinkernagel, Martin Sebastian, Anguita Henríquez, Rodrigo Andrés |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1744-7658 |
Publisher: |
Taylor & Francis |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
31 Oct 2023 08:19 |
Last Modified: |
25 Nov 2023 00:16 |
Publisher DOI: |
10.1080/13543784.2023.2276759 |
PubMed ID: |
37902056 |
Uncontrolled Keywords: |
AMD GA Geographic atrophy avacincaptad pegol complement cascade macular degeneration pegcetacoplan, lampalizumab |
URI: |
https://boris.unibe.ch/id/eprint/188359 |
Actions (login required)
 |
Edit item |